SAN CARLOS, Calif.--September 23, 2026--Glycomine, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to GLM101 for the treatment of phosphomannomutase 2 congenital...
Daiichi Sankyo to Acquire Plexxikon
News | 02. 28. 2011
Plexxikon
Plexxikon Inc. today announced it has entered into a merger agreement with Daiichi Sankyo Company, Limited, a Japan‐based global pharmaceutical company. The purchase price for Plexxikon is $805 million up‐front. Near‐term milestone payments associated with the approval of PLX4032 could total an additional $130 million. Closure of the transaction is subject to clearance under the Hart‐Scott‐Rodino (HSR) Antitrust Improvements Act and customary closing conditions.
